Sensitivity

Transactional demand for central bank digital currency

Retrieved on: 
Jeudi, avril 18, 2024
POS, Learning, CB, E41, Calibration, Financial regulation, Interest, ATM, Oesterreichische Nationalbank, Journal of Macroeconomics, Sensitivity, Diffusion, ITunes, Bank of Canada, P2P, Safety, NBER, Benchmarking, Prevalence, SPACE, Bernoulli, Journal of Monetary Economics, E42, Paper, European Parliamentary Research Service, Apollo, Environment, Political economy, COVID-19, Review of Economic Dynamics, Abramov, Loss, Working paper, Choice, Collection, Probability, Dowd, Castrén, Face, Noise, History, Restaurant, Journal of Political Economy, ECB, Policy, Diary, Model, Utility, Clutch (eggs), Canadian International Council, Journal of Financial Stability, JEL, Digital, Bias, Journal, Research, Classification, CBDC, SARS-CoV-2, ECMI, Credit, Odds ratio, Literature, European Central Bank, Mises Institute, Monetary economics, Section 5, Occupation, E47, Financial intermediary, Government, Supermarket, Friction, Finance, BIS, Love, Bart, The Economic Journal, Education, Risk, Section 4, Privacy, Section 3, Appetite, App Store (iOS/iPadOS), Human, DNB, International finance, Section 2, Leonhard Euler, Payment, Attention, Central bank, Consumer, EPRS, Habit, American Economic Review, Confidence interval, FCO, Central bank digital currency, Exercise, Letizia, Applied economics, Digital currency, Sale, Business cycle, Amazon, Community business development corporation, Control, Chart, Proxy, American Economic Journal, LN, Bank, Fintech, IMF, Analysis, Aggregation, Cryptocurrency
Key Points: 

    Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024

    Retrieved on: 
    Lundi, avril 8, 2024
    General Health, Health, Science, Research, Oncology, Esophagus, Sensitivity, Prostate cancer, Survival rate, Patient, Lung, Exact sciences, Breast, Death, MD, Abstract, AACR, Cancer, Pancreas, Stomach, Liver, Ovary, Medical imaging

    Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test.

    Key Points: 
    • Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test.
    • These results validate the sensitivity and specificity of the company’s multi-biomarker class approach across a broad range of cancer types, including the most aggressive cancers and cancers with no current standard of care for screening.
    • ASCEND-2 is a large, multi-center, prospective, case-control study of over 11,000 clinically characterized participants from a racially, ethnically, and geographically diverse cohort representative of the U.S. population.
    • Key findings: Results showed that in the rare instance when MCED testing detected pre-cancerous conditions in the DETECT-A study, surgical interventions prevented cancer development, and all patients were cancer-free at follow-up.

    Parental avoidance of toxic exposures could help prevent autism, ADHD in children, new study shows

    Retrieved on: 
    Jeudi, mars 28, 2024
    Pesticide, Sensitivity, Xenobiotic, Collaborative writing, Prevalence, ADHD, Cell, Risk, Inflammation, Patient, SAN, School, Anglo-French Wars, Tissue, Research, Miller, Child, Breast, Virus, University, Wane, Doctor of Philosophy, Pregnancy, Causality, Attention deficit hyperactivity disorder, Gulf War, B cell, EPA, CDC, University of Texas System, Fire, Toxicology, Workforce, Public health, TILT, Spectrum, Family, Histamine, Vaccine

    SAN ANTONIO, March 27, 2024 /PRNewswire-PRWeb/ -- Autism and attention deficit hyperactivity disorder (ADHD) may be preventable if parents avoid toxic exposures and adopt interventions such as environmental house calls, according to a published study led by researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio).

    Key Points: 
    • The findings build on a 2015 study by UT Health San Antonio that first linked chemical intolerance in patients with the risk of their children developing autism and ADHD.
    • "Up to now, most interventions have been behavioral or medical, after a child is diagnosed."
    • Still, they wrote, "The implications of this study, if confirmed, could be significant for preventive measures and early intervention strategies in families with parental chemical intolerance.
    • And the prevalence of ADHD has risen to one in eight children, also according to the CDC.

    QSM Diagnostics Enters Distribution Agreement with Cenversa

    Retrieved on: 
    Jeudi, décembre 14, 2023
    Infection, Sensitivity, Animal, Culture, QSM, Health, Veterinarian, Diagnosis, Partnership, Otter, Pseudomonas, Urinalysis, Medical device, Medical imaging, Vaccine

    BOSTON, Dec. 14, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics, a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Cenversa the parent company of Cenquip Pty Ltd, Australia's leader in innovative veterinary equipment and digital imaging solutions for animal health professionals.

    Key Points: 
    • BOSTON, Dec. 14, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics , a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Cenversa the parent company of Cenquip Pty Ltd, Australia's leader in innovative veterinary equipment and digital imaging solutions for animal health professionals.
    • "At Cenversa, we are always looking to innovate when it comes to animal care and health.
    • That's why it is very important for us to have a strategic partner like QSM Diagnostics, as we recognize the importance of proper and timely diagnosis of bacterial infections.
    • "We're very excited to partner with Cenversa and their amazing team," says Ed Goluch, Ph.D., Founder and CEO of QSM Diagnostics.

    Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

    Retrieved on: 
    Jeudi, novembre 9, 2023
    ACRV, Neoplasm, Science, Patient, Research, AACR, IND, AUC, Ovarian cancer, Biomarker, Endometrial cancer, LDG, Conference, WEE1, Development, PKMYT1, Clinical trial, Medicine, PDX, Carcinoma, Sensitivity, Therapy, Cancer, AP3, Pharmaceutical industry, Medical imaging, Cryptocurrency

    WATERTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.

    Key Points: 
    • WATERTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.
    • Net loss for the quarter ended September 30, 2023 was $14.5 million compared to a net loss of $9.2 million for the same period in 2022.
    • Research and development expenses were $10.3 million for the quarter ended September 30, 2023 compared to $7.9 million for the same period in 2022.
    • General and administrative expenses were $5.9 million for the quarter ended September 30, 2023 compared to $1.6 million for the same period in 2022.

    bioMérieux Partners with Industry-Leading Yeast Supplier White Labs to Develop GENE-UP® BREWPRO™ Yeast Slurry (YS) - The First Quality Control Test Kit for Yeast-Specific Applications

    Retrieved on: 
    Mardi, octobre 24, 2023
    Cannabis, YS, Cross, Health, Food, PCR, Software, Euronext Paris, Disease, Situation, task, action, result, Risk assessment, Partnership, Bacteria, Food quality, Accuracy and precision, Infection, Sensitivity, Vaccine, Beer, Medical device, Operation

    CHICAGO, Oct. 24, 2023 /PRNewswire/ -- bioMérieux, a world leader in in vitro diagnostics, announces the launch of GENE-UP® BREWPRO™ Yeast Slurry (YS) - the first-of-its-kind diagnostic quality control PCR test designed to specifically detect contaminants in raw yeast materials and yeast propagations to ensure top quality fermentations. Developed in collaboration with industry-leading yeast supplier White Labs, the solution features an optimized sample prep with increased sensitivity and specialized targets tailor-made for yeast slurries.

    Key Points: 
    • Developed in collaboration with industry-leading yeast supplier White Labs , the solution features an optimized sample prep with increased sensitivity and specialized targets tailor-made for yeast slurries.
    • GENE-UP® BREWPRO™ YS is the first diagnostic quality control PCR test designed for raw yeast materials and propagations.
    • Yeast suppliers and brewers producing their own yeast must navigate numerous spoilage and unwanted bacteria and contamination challenges throughout the harvesting and yeast propagation processes.
    • Current quality control test kits for the brewing industry are designed to detect potential spoilers in the finished product, not in the yeast slurries themselves.

    Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    Retrieved on: 
    Lundi, octobre 16, 2023
    Neoplasm, DNA repair, Biomarker, PDX, Proteomics, ACRV, Development, AACR, DNA, Cancer, AUC, Medicine, Endometrial cancer, Sensitivity, FDA, Therapy, Ovarian cancer, CHK2, Patient, Bladder cancer, Conference, Poster, AP3, Pharmaceutical industry, Mastic (plant resin), Medical imaging

    WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) --  Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, announced data highlighting its AP3 approach to identify and evaluate biomarkers for its OncoSignature assay designed specifically to predict sensitivity to ACR-368, the company’s selective small molecule inhibitor targeting CHK1 and CHK2, currently in registrational-intent Phase 2 clinical trials. The data were presented in two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston this past week.

    Key Points: 
    • The data were presented in two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston this past week.
    • “We leverage this distinctive capability to create drug-tailored OncoSignature assays as a companion diagnostic aiming to identify and treat patients most likely to benefit from treatment.
    • Biomarker candidates were initially evaluated through pathway reconstitution and in cellular functional assays, after which they were assembled into the ACR-368 OncoSignature assay for further functional validation.
    • These data support the use of the company’s ACR-368 OncoSignature assay in its ongoing registrational-intent Phase 2 clinical trials, and demonstrate the distinctive, practical application of the company’s AP3 platform.

    Optilogic's Groundbreaking Sensitivity at Scale Enables Large-Scale Sensitivity Analysis With a Single Click

    Retrieved on: 
    Jeudi, septembre 21, 2023
    Sensitivity, Software as a service, Transport, Workflow, ANN, Risk, Scale, Food delivery

    ANN ARBOR, Mich., Sept. 21, 2023 /PRNewswire/ -- Supply chain network design software innovator, Optilogic, is making true large-scale sensitivity analysis possible with Sensitivity at Scale, which runs hundreds or thousands of sensitivity scenarios in parallel with a single click.

    Key Points: 
    • Sensitivity at Scale runs hundreds or thousands of sensitivity scenarios in parallel with a single click in its SaaS-based Cosmic Frog supply chain design platform.
    • ANN ARBOR, Mich., Sept. 21, 2023 /PRNewswire/ -- Supply chain network design software innovator, Optilogic , is making true large-scale sensitivity analysis possible with Sensitivity at Scale , which runs hundreds or thousands of sensitivity scenarios in parallel with a single click.
    • This groundbreaking innovation in supply chain sensitivity analysis is available today in Optilogic Cosmic Frog , the only 100-percent SaaS-native supply chain design platform.
    • Cosmic Frog removes these barriers by enabling large-scale sensitivity analysis with a single click of the "Sensitivity at Scale" button.

    QSM Diagnostics Enters Distribution Agreement with Deiko

    Retrieved on: 
    Mardi, juillet 25, 2023
    Partnership, Veterinarian, Pseudomonas, Sensitivity, Animal, Otter, Diagnosis, Infection, Culture, Health, QSM, Urinalysis, Medical device, Medical imaging, Vaccine

    BOSTON, July 25, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics, a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Deiko, a holding company with over 30 years of experience, specializing in the distribution of consumables for veterinarians.

    Key Points: 
    • BOSTON, July 25, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics, a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Deiko, a holding company with over 30 years of experience, specializing in the distribution of consumables for veterinarians.
    • "At Deiko, we are always looking to innovate when it comes to animal care and health.
    • That's why it is very important for us to have a strategic partner like QSM Diagnostics, as we recognize the importance of proper and timely diagnosis of bacterial infections.
    • "We're very excited to partner with Deiko and their amazing team," says Ed Goluch, Ph.D., Founder and CEO of QSM Diagnostics.

    QSM Diagnostics Inks Distribution Agreement with Penn Veterinary Supply

    Retrieved on: 
    Vendredi, juin 16, 2023
    Veterinarian, Infection, Culture, Supply, Sensitivity, Partnership, QSM, Veterinary medicine

    BOSTON, June 16, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics, a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Penn Veterinary Supply, an independent U.S. regional distributor of veterinary products and services.

    Key Points: 
    • BOSTON, June 16, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics , a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Penn Veterinary Supply , an independent U.S. regional distributor of veterinary products and services.
    • The distribution agreement will enable practices in Penn Veterinary's Supply network access to QSM Diagnostics suite of products.
    • "We love Penn Vet's dedication to providing value for their partners," says Ed Goluch, Ph.D., Founder and CEO of QSM Diagnostics.
    • "This partnership will allow us to provide veterinarians more quality options for how bacterial infections are diagnosed and treated by getting our suite of products in their practices."